Furthermore, post-transplantation status and the use of drugs such as everolimus have been shown not only to favor atherosclerosis and CVD incidence, but also increase PCSK9 levels to a greater extent, and this can cause well- or less-known consequences: in fact, in addition to causing an increase in plasma levels of LDL and probably favoring post-transplant diabetes mellitus, it remains to be clarified whether elevation in PCSK9 levels can influence graft survival. Here, PCSK9 is linked to atherosclerosis.